O
Ocular Therapeutix, Inc. (OCUL)
NGM – Real Time Price. Currency in USD
9.16
-0.12 (-1.29%)
At close: May 12, 2026, 4:00 PM EDT
9.23
+0.07 (0.76%)
After-hours: May 12, 2026, 7:02 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
9.16
-0.12 (-1.29%)
At close: May 12, 2026, 4:00 PM EDT
9.23
+0.07 (0.76%)
After-hours: May 12, 2026, 7:02 PM EDT
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Name | Position |
|---|---|
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer |
| Dr. Peter K. Jarrett Ph.D. | Chief Technical Officer |
| Dr. Peter K. Kaiser M.D. | Chief Development Officer |
| Dr. Pravin U. Dugel M.D. | Executive Chairman, President & CEO |
| Mr. Barry Rubenstein M.S. | Chief Human Resources Officer |
| Mr. Donald Notman Jr. | CFO, COO & Principal Accounting Officer (Leave of Absence) |
| Mr. Jason Robins | Senior VP of Finance, Interim CFO & Principal Accounting Officer |
| Mr. Todd D.C. Anderman J.D. | Chief Legal Officer & Corporate Secretary |
| Mr. William H. Ransone II | Vice President of Global Sales & Marketing |
| Mr. William S. Slattery Jr. | Vice President of Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | tm2613442d1_8k.htm |
| 2026-05-05 | 10-Q | ocul-20260331x10q.htm |
| 2026-04-30 | DEF 14A | ocul-20260611xdef14a.htm |
| 2026-02-27 | 8-K | tm267471d2_8k.htm |
| 2026-02-05 | 8-K | tm265061d1_8k.htm |
| 2026-02-05 | 10-K | ocul-20251231x10k.htm |
| 2026-01-23 | 8-K | tm263902d1_8k.htm |
| 2025-12-18 | 8-K | tm2533889d1_8k.htm |
| 2025-12-05 | 8-K | tm2532882d1_8k.htm |
| 2025-11-04 | 8-K | tm2530039d1_8k.htm |